Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL OPUS IV
- Development stage
- Preclinical
- Lead developer
- Biolingus
- Modality
- Peptides
- Administration
- Sublingual
01
Overview
**BL OPUS IV** is a preclinical, sublingual fixed-dose combination being developed by BioLingus for **type 2 diabetes mellitus**. It combines insulin, which activates the insulin receptor to promote glucose uptake and suppress hepatic glucose output, with exenatide, a glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion and supports glycemic control. The product uses BioLingus' OPUS sublingual peptide and protein delivery technology to provide a needle-free formulation.
- Other names
- Sublingual insulin+
02
Targets
INSR (Insulin receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on BL OPUS IV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL OPUS IV.